期刊文献+

质谱在金属抗癌药物与蛋白质相互作用研究中的应用 被引量:7

Application of Mass Spectrometry in Research on the Interactions of Anticancer Metallodrugs with Proteins
在线阅读 下载PDF
导出
摘要 研究细胞毒性金属抗肿瘤药物与蛋白质的相互作用,以及这种相互作用对药物的细胞摄入、转运、代谢和生物利用度的影响,对金属抗癌药物的结构设计和优化,提高药物的抗癌活性,降低毒副作用具有重要意义。基于软电离技术的电喷雾质谱和基质辅助激光解析电离质谱能够在分析检测过程中很好的保留金属抗癌药物与蛋白质的共价(配位)结合,获得药物与蛋白质结合位点的信息。同时,质谱分析还具有灵敏度高,所需样品量少,耗时短以及适用于分析复杂生物样品等优点,已成为研究金属抗癌药物与蛋白质相互作用最强有力的工具,在为药物发现提供大量化学、生物信息的同时,也极大地促进了质谱技术自身的发展。本文将结合我们在金属抗癌药物相互作用组学研究中取得的最新进展,系统地总结、评述Bottom-up和Top-down质谱分析方法在铂、钌类金属抗癌药物与蛋白质相互作用研究中的发展动态,并分析这一前沿交叉领域未来的发展趋势。 Investigating the interactions of anticancer metallodrugs with proteins,as well as their effects on the process of drug transport,cellular uptake,metabolism and bioavailability,is very important for structure-based design,improvement of activity and reduction of side effects of anticancer metallodrugs.The soft ionization mass spectrometry including ESI and MALDI can greatly preserve the coordination of drug molecules to biomolecules during the performance,and provide direct information on the binding sites of metallodrugs on proteins.Additionally,mass spectrometry has many advantages such as high sensitivity,low sample consumption,speed,suitable for complex biological samples and so on.Thus,it has become the most powerful tool for studying the interactions of anticancer metallodrugs with proteins.The increasing researches on this field provide not only valuable chemical and biological information for drug discovery,but also greatly promote mass spectrometry itself.Bases on the update progress of our own group on the interactomic studies of anticancer metallodrugs,we presents a review of the latest achievements of research on the interactions of platinum-and ruthenium-based anticancer drugs(or candidates) with proteins using bottom-up and top-down mass spectrometric approaches.A brief analysis on the possible future research trends and development in this area is also given.
出处 《质谱学报》 EI CAS CSCD 2010年第6期354-361,共8页 Journal of Chinese Mass Spectrometry Society
基金 国家自然科学基金(20975103,90713020) 科技部973重大基础研究项目(2007CB935601)资助
关键词 质谱 金属抗癌药物 蛋白质 相互作用 mass spectrometry anticancer metallodrug protein interaction
作者简介 胡文兵(1983~),男(汉族),博士研究生,分析化学专业。E—mail:wenbhu@iecas.ac.cn 通信作者:汪福意(1964~),男(汉族),研究员,博士生导师。E-mail:fuyi.wang@iotas.ac.cn
  • 相关文献

参考文献49

  • 1WANG D,LIPPARD S J.Cellular processing of platinum anticancer drugs[J].Nature Reviews Drug Discovery,2005,4(4):307-320.
  • 2OZOLS R F.Ovarian cancer:New clinical approaches[J].Cancer Treatment Reviews,1991,18(Suppl 1):77-83.
  • 3TODD R C,LIPPARD S J.Inhibition of transcription by platinum antitumor compounds[J].Metallomics,2009,1(4):280-291.
  • 4KELLAND L.The resurgence of platinum-based cancer chemotherapy[J].Nature Reviews:Cancer,2007,7(8):573-584.
  • 5JUNG Y W,LIPPARD S J.Direct cellular responses to platinum-induced DNA damage[J].Chemical Reviews,2007,107(5):1 387-1 407.
  • 6TIMERBAEV A R,HARTINGER C G,ALEKSENKO S S,et al.Interactions of antitumor metallodrugs with serum proteins:Advances in characterization using modern analytical methodology[J].Chemical Reviews,2006,106(6):2 224-2 248.
  • 7GIBSON D.The mechanism of action of platinum anticancer agents-what do we really know about it?[J].Dalton Transactions,2009,48:10 681-10 689.
  • 8HARTINGER C G,TSYBIN Y O,FUCHSER J,et al.Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach[J].Inorganic Chemistry,2008,47(1):17-19.
  • 9ESTEBAN-FERNANDEZ D,MORENO-GORDALIZA E,CANAS B,et al.Analytical methodologies for metallomics studies of antitumor Ptcontaining drugs[J].Metallomics,2010,2 (1):19-38.
  • 10KHALAILA I,BERGAMO A,BUSSY F,et al.The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy[J].International Journal of Oncology,2006,29(1):261-268.

二级参考文献75

共引文献23

同被引文献55

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部